Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PLA2G2A | P14555 | 8/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 3/20 | 0.31 |
| ▸ | RXRA | P19793 | 1/20 | 0.30 |
| ▸ | RXRB | P28702 | 1/20 | 0.30 |
| ▸ | RXRG | P48443 | 1/20 | 0.30 |
| ▸ | SCN10A | Q9Y5Y9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7484806 | 0.79 | FLT3 (0.34) | PLA2G2A | |
| SCHEMBL7485079 | 0.78 | LCK (0.36) | PLA2G2A | |
| SCHEMBL8195566 | 0.75 | ESR1 (0.38) | PLA2G2A | |
| SCHEMBL7481184 | 0.74 | POLB (0.40) | — | |
| SCHEMBL7490660 | 0.68 | BACE1 (0.39) | PLA2G2A | |
| SCHEMBL7485060 | 0.68 | SMN1; SMN2 (0.40) | — | |
| SCHEMBL8196356 | 0.68 | HSD17B10 (0.42) | RXRARXRBRXRG | |
| SCHEMBL8196527 | 0.67 | FLT3 (0.41) | — | |
| SCHEMBL8253524 | 0.65 | MAPT (0.45) | — | |
| SCHEMBL7485862 | 0.65 | KDM4E (0.47) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1204644-A1 | SYNTHESIS OF SUBSTITUTED AMIDINES | ELI LILLY AND COMPANY (US) | 2002-05-15 | — | — | EP | disclosed |
| WO-2000078725-A1 | SYNTHESIS OF SUBSTITUTED AMIDINES | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |
| WO-2000078724-A2 | IMIDAZOLINDERIVATIVES THEIR PREPARATION AND THEIR PHARMACEUTICAL USE | ELI LILLY AND COMPANY (US) | 2000-12-28 | — | — | WO | disclosed |